Article
Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.
Diabetes care - 1 Oct 2015
Xu Tao, Brandmaier Stefan, Messias Ana C, Herder Christian, Draisma Harmen H M, Demirkan Ayse, Yu Zhonghao, Ried Janina S, Haller Toomas, Heier Margit, Campillos Monica, Fobo Gisela, Stark Renee, Holzapfel Christina, Adam Jonathan, Chi Shen, Rotter Markus, Panni Tommaso, Quante Anne S, He Ying, Prehn Cornelia, Roemisch-Margl Werner, Kastenmüller Gabi, Willemsen Gonneke, Pool René, Kasa Katarina, van Dijk Ko Willems, Hankemeier Thomas, Meisinger Christa, Thorand Barbara, Ruepp Andreas, Hrabé de Angelis Martin, Li Yixue, Wichmann H-Erich, Stratmann Bernd, Strauch Konstantin, Metspalu Andres, Gieger Christian, Suhre Karsten, Adamski Jerzy, Illig Thomas, Rathmann Wolfgang, Roden Michael, Peters Annette, van Duijn Cornelia M, Boomsma Dorret I, Meitinger Thomas, Wang-Sattler Rui
Abstract excerpt
OBJECTIVE: Metformin is used as a first-line oral treatment for type 2 diabetes (T2D). However, the underlying mechanism is not fully understood. Here, we aimed to comprehensively investigate the pleiotropic effects of metformin. RESEARCH DESIGN AND METHODS: We analyzed both metabolomic and genomic data of the population-based KORA cohort. To evaluate the effect of metformin treatment on metabolite...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.